Research graph
References from Systemic therapy for hepatocellular carcinoma. Local targets link to admitted publications; unresolved targets remain external evidence.
10.1002/ijc.25516
10.1002/ijc.25516 · External reference
10.1002/hep.20933
10.1002/hep.20933 · External reference
10.1053/jhep.2003.50047
10.1053/jhep.2003.50047 · External reference
10.1056/nejmoa0708857
10.1056/nejmoa0708857 · External reference
10.18632/oncotarget.466
10.18632/oncotarget.466 · External reference
10.1158/1078-0432.ccr-12-2791
10.1158/1078-0432.ccr-12-2791 · External reference
10.1155/2013/417894
10.1155/2013/417894 · External reference
10.1148/radiol.11110144
10.1148/radiol.11110144 · External reference
10.1007/s00270-009-9711-7
10.1007/s00270-009-9711-7 · External reference
10.1200/jco.2012.44.1659
10.1200/jco.2012.44.1659 · External reference
10.1200/jco.2012.48.2703
10.1200/jco.2012.48.2703 · External reference
10.1016/j.jvir.2013.03.002
10.1016/j.jvir.2013.03.002 · External reference
10.1002/hep.26487
10.1002/hep.26487 · External reference
10.1200/jco.2012.30.4_suppl.lba154
10.1200/jco.2012.30.4_suppl.lba154 · External reference
10.1055/s-2007-1007122
10.1055/s-2007-1007122 · External reference
10.1016/j.critrevonc.2011.10.008
10.1016/j.critrevonc.2011.10.008 · External reference
10.1016/j.ejca.2011.05.007
10.1016/j.ejca.2011.05.007 · External reference
10.1007/s00270-010-0086-6
10.1007/s00270-010-0086-6 · External reference
10.1002/cncr.27859
10.1002/cncr.27859 · External reference
10.1016/j.ejca.2013.05.011
10.1016/j.ejca.2013.05.011 · External reference
10.1016/j.jhep.2012.06.014
10.1016/j.jhep.2012.06.014 · External reference
10.1016/j.ejca.2011.12.006
10.1016/j.ejca.2011.12.006 · External reference
10.1016/s1470-2045(08)70285-7
10.1016/s1470-2045(08)70285-7 · External reference
10.1200/jco.2011.29.15_suppl.4000
10.1200/jco.2011.29.15_suppl.4000 · External reference
10.1111/j.1742-1241.2012.02940.x
10.1111/j.1742-1241.2012.02940.x · External reference
10.1155/2013/931972
10.1155/2013/931972 · External reference
Phase III trial of linifanib versus sorafenib in patients with advanced hepatocellular carcinoma (HCC).
2012 · External reference
10.1200/jco.2012.48.4410
10.1200/jco.2012.48.4410 · External reference
10.1200/jco.2010.28.15_suppl.4083
10.1200/jco.2010.28.15_suppl.4083 · External reference
10.1097/coc.0b013e3182118cdf
10.1097/coc.0b013e3182118cdf · External reference
10.1007/s00280-010-1320-2
10.1007/s00280-010-1320-2 · External reference
Phase I/II study of lenvatinib (E7080), a multitargeted tyrosine kinase inhibitor, in patients (pts) with advanced hepatocellular carcinoma (HCC): Phase I results.
2012 · External reference
10.1158/1078-0432.ccr-11-0793
10.1158/1078-0432.ccr-11-0793 · External reference
10.1002/cncr.22829
10.1002/cncr.22829 · External reference
10.1007/s00280-009-0927-7
10.1007/s00280-009-0927-7 · External reference
10.1158/1078-0432.ccr-09-0465
10.1158/1078-0432.ccr-09-0465 · External reference
10.1200/jco.2010.33.9432
10.1200/jco.2010.33.9432 · External reference
10.1200/jco.2011.41.2395
10.1200/jco.2011.41.2395 · External reference
10.1111/apt.12132
10.1111/apt.12132 · External reference
10.1001/jama.2010.1672
10.1001/jama.2010.1672 · External reference
10.1200/jco.2012.44.5643
10.1200/jco.2012.44.5643 · External reference
10.1200/jco.2008.18.3301
10.1200/jco.2008.18.3301 · External reference
10.1159/000335963
10.1159/000335963 · External reference
10.1159/000350841
10.1159/000350841 · External reference
10.1097/coc.0b013e318248d83f
10.1097/coc.0b013e318248d83f · External reference
10.1200/jco.2012.30.15_suppl.4099
10.1200/jco.2012.30.15_suppl.4099 · External reference
Phase II study of capecitabine, oxaliplatin, and cetuximab for advanced hepatocellular carcinoma.
2011 · External reference
10.1002/cncr.23489
10.1002/cncr.23489 · External reference
10.1016/j.jhep.2013.07.029
10.1016/j.jhep.2013.07.029 · External reference
10.1158/1078-0432.ccr-11-2175
10.1158/1078-0432.ccr-11-2175 · External reference
10.1200/jco.2012.30.15_suppl.4008
10.1200/jco.2012.30.15_suppl.4008 · External reference
10.1158/1078-0432.ccr-11-1991
10.1158/1078-0432.ccr-11-1991 · External reference
10.1200/jco.2012.47.3009
10.1200/jco.2012.47.3009 · External reference
10.1016/j.ejca.2013.05.028
10.1016/j.ejca.2013.05.028 · External reference
10.1159/000320363
10.1159/000320363 · External reference
A Phase II trial of second-line axitinib following prior antiangiogenic therapy in advanced hepatocellular carcinoma (HCC).
2012 · External reference
10.1002/cncr.26165
10.1002/cncr.26165 · External reference
10.1200/jco.2012.30.15_suppl.4006
10.1200/jco.2012.30.15_suppl.4006 · External reference
10.1200/jco.2012.30.15_suppl.4007
10.1200/jco.2012.30.15_suppl.4007 · External reference
10.1007/s10637-012-9808-8
10.1007/s10637-012-9808-8 · External reference
10.1007/s12032-012-0208-x
10.1007/s12032-012-0208-x · External reference
10.1038/nm.3089
10.1038/nm.3089 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
